SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending amid discussions about potential government equity stakes in quantum computing firms, sparking debates about the significance of this funding. Community members are weighing the potential impact of government involvement, while some express concerns about the company's valuation and long-term prospects within the broader quantum computing sector.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum ($QBTS) is trending amid discussions around potential government investment in quantum computing firms, sparked by WSJ reports. The community is debating the implications of government stakes, with some viewing it as a positive catalyst while others express skepticism, calling it a "pump and dump". Despite some bearish sentiment and a recent dip, the stock is still up significantly over the past year, and many see quantum computing as a high-potential sector.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending amidst discussions about government investment in quantum computing and a newly achieved world record in quantum performance, spurring debates about the company's valuation and long-term potential. Community members are actively analyzing its technical setup, anticipating potential short squeezes, and weighing the impact of insider sales. There's also discussion around IONQ compared to its peers in the quantum computing sector and other high-growth tech areas like AI.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ Corp is trending due to recent news regarding quantum computing investments and the company's upcoming chip release, sparking bullish sentiment among investors. The community is actively discussing potential short squeezes and the company's future prospects in the quantum sector, despite some concerns about dilution. Overall, there is excitement around the potential for government funding and increasing demand for quantum security solutions.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's stock is trending amid discussions on its Q3 earnings, particularly regarding margin compression and revenue. Community members are debating the company's progress in full self-driving (FSD) and its potential impact on future growth. Discussions also involve Elon Musk's compensation package and its implications for shareholder value.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as discussions revolve around its merger with Infleqtion, a quantum computing company, and potential government contracts. Community members are weighing the impact of Elon Musk's recent tweet on quantum computing while also noting potential upcoming exposure at an NVIDIA conference. Some traders believe $CCCX is undervalued compared to its peers in the quantum computing sector.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is trending amid discussions of potential equity stakes from the Trump administration, as reported by the WSJ, sparking excitement and calls to "go USA." The news is seen as a catalyst for growth in the sector, though some caution against potential risks and market manipulation; community members are pointing to Black Rock's prior investment as validation.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is trending as traders discuss its potential in quantum-safe Bitcoin and its recent demonstration of quantum-resistant cryptography. Community members highlight the company's potential to protect against quantum attacks and emphasize its advantageous positioning compared to competitors. Some are also excited about potential upcoming media exposure and are speculating about government interest in the quantum computing space.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors digest Q3 2025 results, including the shipment of B1 cell samples and news of a second OEM JDA, marking progress toward commercialization. The community is actively discussing potential OEM partners and the company's extended cash runway, viewing these as positive signals. Some are drawing connections to Tesla and solid-state battery technology, while others remain skeptical, pointing to continued losses and a long path to revenue.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group N.V. ($NBIS) is trending amid discussions about its AI infrastructure buildout and recent stock performance, with some investors expressing concern over the stock's pullback despite positive developments like the partnership with Uber for Avride. Community members are debating the company's valuation, potential catalysts like earnings and further deals, and whether the recent drop represents a buying opportunity or a sign of broader market concerns impacting AI-related stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a...

Retail investor interest in Q32 Bio Inc picked up on Wednesday after the clinical-stage biotech said the U.S. Food and Drug Administration granted Fast Track designation to its experimental treatment for alopecia areata.The drug, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody being tested in a Phase 2 trial for alopecia areata (AA), an autoimmune disorder that causes hair loss.&nbsp;The Fast Track status is intended to speed development of therapies that address serious conditions and unmet medical needs."The Fast Track designation granted by the FDA recognizes the seriousness of AA and the significant current unmet medical need while underscoring bempikibart's potential as a novel, differentiated therapy," said Q32 Bio Chief Executive Jodie Morrison in a statement.Bempikibart is designed to re-regulate immune function by blocking IL-7 and TSLP signaling pathways, key components in autoimmune activity.&nbsp;The company recently began dosing patients in both an open-label extension and Part B of its SIGNAL-AA trial following encouraging early results.The FDA designation allows for more frequent meetings with the agency, eligibility for priority review, and the possibility of accelerated approval, subject to clinical results.On Stocktwits, 24-hour message volume for Regulus jumped by 1,600% amid bullish sentiment.Some users highlighted the stock’s low float and recent FDA news as drivers for a potential swing trade, while others noted that the therapy itself — bempikibart — is making steady clinical progress.&nbsp;<stembedurl>https://stocktwits.com/onlyfactshere/message/613083538</stembedurl>One user pointed to the Fast Track status as a key catalyst, potentially accelerating development timelines for a treatment area with few approved options.&nbsp;<stembedurl>https://stocktwits.com/ALOSETE/message/613089756</stembedurl>Still, some cautioned that despite promising Phase 2 data, the company’s limited cash runway — estimated at about five quarters — underscores the inherent risks of biotech investing.<stembedurl>https://stocktwits.com/Rage_Against_The_Machine/message/613078123</stembedurl>Shares of Q32 Bio have declined 1.9% year-to-date, underperforming the Nasdaq, which is down 1.6%, but faring better than the Dow and S&amp;P 500, which have fallen 4.1% and 5.1%, respectively, over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A photo illustration showing a mix of various tablets and pharmaceutical products, primarily manufactured by U.S. pharmaceutical companies, photographed in Edmonton, Alberta, Canada, on April 10, 2025 (Photo by Artur Widak/NurPhoto via Getty Images)

Q32 Bio Stock Turns Retail Trader Heads After FDA Grants Fast Track For Alopecia Drug

Q32 Bio shares drew renewed attention on Wednesday after the FDA granted Fast Track designation to its experimental alopecia areata treatment, bempikibart. The designation could accelerate development and review of the Phase 2-stage therapy.

Equity

Q32 Bio to Participate in Upcoming March Investor Conferences

Q32 Bio to Participate in Upcoming March Investor Conferences Q32 Bio to Participate in Upcoming March Investor Conferences PR Newswire WALTHAM, Mass., Feb. 26, 2025 WALTHAM, Mass., Feb. 26, 2025...

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in...

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference PR Newswire WALTHAM...

Shares of Q32 Bio (QTTB) plummeted over 60% in premarket trading Wednesday following mixed results from Phase 2a trials of its lead candidate, bempikibart (ADX-914).&nbsp;The clinical-stage biotech company is under heavy selling pressure, with retail sentiment turning ‘extremely bearish’ on Stocktwits amid a spike in message volume.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/QTTB_sentiment_and_message_volume_on_Dec_11_5dea79b168.png" alt="QTTB sentiment and message volume on Dec 11.png" width="1318" height="324"><figcaption>QTTB sentiment and message volume on Dec 11 as of 8:30 am ET | source: Stocktwits</figcaption></figure>The SIGNAL-AA trial for alopecia areata showed “encouraging” clinical activity, with a mean reduction of 16% in the Severity of Alopecia Tool (SALT) score for bempikibart recipients versus 2% in the placebo group at 24 weeks.&nbsp;However, only 9% of bempikibart patients achieved SALT-20, compared to none in the placebo group.Meanwhile, the SIGNAL-AD trial for atopic dermatitis failed to meet its primary endpoint in Part B, with patients receiving bempikibart showing a 74% improvement in the Eczema Area and Severity Index at 14 weeks, compared to 76% in the placebo group.&nbsp;CEO Jodie Morrison expressed disappointment, citing plans to review the data to understand the high placebo rate and trial outcomes better.The mixed results prompted a series of downgrades:• Wells Fargo cut its rating to ‘Equal Weight’ from ‘Overweight’ and slashed its price target to $16 from $95, citing disappointing atopic dermatitis results and concerns over Q32’s cash needs.• Leerink lowered its rating to ‘Market Perform’ from ‘Outperform’, with a price target of $9, down from $68. The firm removed atopic dermatitis value from its model and noted uncertainty around alopecia areata progression.• Raymond James downgraded Q32 Bio to ‘Outperform’ from ‘Strong Buy’, with its price target falling to $22 from $90. Analyst Steven Seedhouse highlighted underestimated market reaction but acknowledged the potential of the IL7R-4 mechanism.• Oppenheimer reduced its price target to $20 from $80 while maintaining an ‘Outperform’ rating, citing the alopecia opportunity’s potential despite setbacks in atopic dermatitis.Despite the sharp decline, QTTB shares remain up over 120% year-to-date.&nbsp;However, near-term sentiment and confidence in the stock have been severely dented, with investors awaiting further clarity on the drug’s development plans.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Q32 Bio Stock Plunges After Analyst Downgrades, Price-Target Slashes Over Alopecia Data: Retail Confidence Drops

CEO Jodie Morrison expressed disappointment, citing plans to review the data to understand the high placebo rate and trial outcomes better

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing...

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Nov...

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 Q32 Bio to Present Tissue-Targeted...

Q32 Bio to Participate in Upcoming September Investor Conferences

Q32 Bio to Participate in Upcoming September Investor Conferences Q32 Bio to Participate in Upcoming September Investor Conferences PR Newswire WALTHAM, Mass., Aug. 29, 2024 WALTHAM, Mass., Aug. 29...

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$1.19	--	--	N/A
Q2 '25	-$0.98	-$0.78	20.27%	BEAT
Q1 '25	-$1.23	-$0.90	26.83%	BEAT
Q4 '24	-$1.51	-$1.16	23.19%	BEAT
Q3 '24	-$1.38	-$1.46	-5.87%	MISSED

QTTB
Q32 Bio Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest QTTB News

QTTBQ32 Bio Inc.